CN106621077A - Hollowed-out gold mark and gold mark location device - Google Patents
Hollowed-out gold mark and gold mark location device Download PDFInfo
- Publication number
- CN106621077A CN106621077A CN201710067198.9A CN201710067198A CN106621077A CN 106621077 A CN106621077 A CN 106621077A CN 201710067198 A CN201710067198 A CN 201710067198A CN 106621077 A CN106621077 A CN 106621077A
- Authority
- CN
- China
- Prior art keywords
- gold mark
- sample body
- hollow out
- golden sample
- main body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000010931 gold Substances 0.000 title claims abstract description 78
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 title claims abstract description 77
- 229910052737 gold Inorganic materials 0.000 title claims abstract description 77
- 239000003814 drug Substances 0.000 claims abstract description 65
- 239000007800 oxidant agent Substances 0.000 claims description 12
- 230000001590 oxidative effect Effects 0.000 claims description 12
- 229910001069 Ti alloy Inorganic materials 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 238000003491 array Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 24
- 206010028980 Neoplasm Diseases 0.000 abstract description 20
- 238000011282 treatment Methods 0.000 abstract description 13
- 210000001519 tissue Anatomy 0.000 abstract description 8
- 238000001514 detection method Methods 0.000 abstract description 5
- 210000004872 soft tissue Anatomy 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000013268 sustained release Methods 0.000 abstract 2
- 239000012730 sustained-release form Substances 0.000 abstract 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
- 239000002105 nanoparticle Substances 0.000 description 9
- 229920002101 Chitin Polymers 0.000 description 8
- 238000001959 radiotherapy Methods 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 239000005018 casein Substances 0.000 description 7
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 7
- 235000021240 caseins Nutrition 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 229920001661 Chitosan Polymers 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229940009456 adriamycin Drugs 0.000 description 4
- 230000000118 anti-neoplastic effect Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000002539 nanocarrier Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- -1 NP) Substances 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 239000003364 biologic glue Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 238000002727 particle therapy Methods 0.000 description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229910001020 Au alloy Inorganic materials 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 229920000869 Homopolysaccharide Polymers 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000016408 Podocarpus macrophyllus Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 244000162450 Taxus cuspidata Species 0.000 description 1
- 235000009065 Taxus cuspidata Nutrition 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940058573 b-d glucose Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005426 magnetic field effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000002673 radiosurgery Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000033912 thigmotaxis Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1007—Arrangements or means for the introduction of sources into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1028—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy using radiation sources applied onto the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1048—Monitoring, verifying, controlling systems and methods
- A61N5/1049—Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
- A61N2005/1087—Ions; Protons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a hollowed-out gold mark and a gold mark location device. The hollowed-out gold mark comprises a gold mark main body, wherein a first through hole is formed in the gold mark main body along an axis of the gold mark main body; the gold mark main body is hollowed-out; a plurality of drug sustained release boxes are kept in the first through hole; a plurality of second through holes are formed in the gold mark main body in a radial direction of the gold mark main body; and the gold mark main body is of a hollowed-out structure. According to the hollowed-out gold mark provided by the invention, the gold mark main body is represented as the hollowed-out structure through the second through holes in the gold mark main body, so that the stability of the gold mark main body and tumor tissues or surrounding special soft tissues thereof where the gold mark main body is implanted is enhanced, and subsequently, the gold mark main body is prevented from moving easily, detection precision is enhanced and the accuracy of a detection result is guaranteed; and by keeping the plurality of drug sustained release boxes in the first through hole, treatment on patients is facilitated; and the hollowed-out gold mark has the advantages of being simple in structure, convenient to use and the like.
Description
Technical field
The present invention relates to medical instruments field, more particularly to a kind of hollow out gold mark and gold mark positioner.
Background technology
The means for the treatment of tumour are using radiotherapy sides such as stereotaxis, proton therapeutic, heavy particle therapy, linear accelerators
Formula, radiotherapy is one of the important means for carrying out oncotherapy.The purpose of tumour radiotherapy is maximum to tumor target
Therapeutic dose, and make the exposure dose of normal structure around tumour and absorbed organ minimum, so as to improve the local controlled of tumour
Rate processed, reduces the complication of normal structure.Therefore, radiotherapy must accomplish " Precise Diagnosis, careful design, be accurately positioned, essence
Really treatment ".Positioning of the prior art to target organ, is all mostly by being implanted into gold mark on the organ-tissue, with to golden target
Localization method come complete to target organ tissue positioning.
The rich knife of match is a kind of stereotactic irradiation machine, incorporates image-guided system, high accuracy robotic tracking and aims at
System and ray release irradiation system, can complete the treatment of any site morbidity.The light-duty straight line that can produce 6MVX lines by one
Electron accelerator is placed in one to be had on the mechanical arm of 6 frees degree, by computing x-ray video camera and x-ray image processing system
The low dosage 3-dimensional image of gained performs treatment plan following the trail of target location, and with the radioactive ray of correct dose " excision " is come.
The rich knife of match is high-precision radiosurgery technology, by image-guided, once or for several times heavy dose of height
Energy roentgen radiation x is on tumor tissues.
If not can determine that the position of tumour on image, cannot also implement high accuracy treatment.Therefore, it is swollen in order to show
The anatomical position of knurl, before the treatment, it is necessary to the implanted metal label around tumour, so as to carry out matching can when rich knife is treated
The position of tracking of knub, implements not only fast but also accurately treats, and it is mainly applied in the treatment of thorax abdomen internal organs.Due to thorax abdomen
Without fixed position relationship between internal organs and the bone mark of body, therefore first have to implantation mark around tumor tissues or its
Note thing (internal labeling thing), this label should in position keep being relatively fixed with knurl body, used as the detection mark of x-ray tracking system
Know.
But label is organized or around it after specific soft tissue in implantation tumour, label is susceptible to movement, affects
Testing result, and label cannot carry substantial amounts of medicine, be not easy to treatment.
The content of the invention
It is an object of the invention to provide a kind of hollow out gold is marked with and gold mark emitter, to solve present in prior art
Label is organized or around it after specific soft tissue in implantation tumour, and label is susceptible to movement, affects testing result, and is marked
Note thing cannot carry substantial amounts of medicine, be not easy to the technical problem treated.
The hollow out gold mark that the present invention is provided, including golden sample body, the golden sample body offers first through hole along its axis,
The golden sample body is in hollow shape, and multiple medicament slow release casees are placed with the first through hole, and the golden sample body is radially
Multiple second through holes are opened up, the golden sample body is engraved structure.
Further, the golden sample body is hollow cylindrical.
Further, a diameter of 0.1mm-1.5mm of the golden sample body.
Further, second through hole is circular shrinkage hole array, plum blossom-shaped hollow out array Huo Swastika shape hollow out arrays.
Further, the length of the golden sample body is 0.1mm-10mm.
Further, the medicament slow release case is bonded on the golden sample body by connecting oxidant layer.
Further, the connection oxidant layer is made a living thing adhesive phase.
Further, the golden sample body is made up of proof gold.
Further, the golden sample body is made up of titanium alloy.
A kind of gold mark positioner, including described hollow out gold mark are still further provides, wherein, also include corresponding to described
The X-ray emitter that golden sample body is arranged.
The hollow out gold that the present invention is provided is marked with and gold mark emitter, has the advantage that：
The hollow out gold mark that the present invention is provided, including golden sample body, the golden sample body offers first through hole along its axis,
The golden sample body is in hollow shape, and multiple medicament slow release casees are placed with the first through hole, and the golden sample body is radially
Multiple second through holes are opened up, the golden sample body is engraved structure.The hollow out gold mark that the present invention is provided is by golden sample body
Second through hole makes golden sample body for the tumor tissues or the specific soft tissue around it of engraved structure, the golden sample body of increase and implantation
Stability, make golden sample body be not susceptible to movement, improve accuracy of detection, it is ensured that the accuracy of testing result；And it is logical first
Multiple medicament slow release casees are placed in hole and is easy to the treatment to patient, be simple in structure and convenient in use.
Description of the drawings
In order to be illustrated more clearly that the specific embodiment of the invention or technical scheme of the prior art, below will be to concrete
The accompanying drawing to be used needed for embodiment or description of the prior art is briefly described, it should be apparent that, in describing below
Accompanying drawing is some embodiments of the present invention, for those of ordinary skill in the art, before creative work is not paid
Put, can be with according to these other accompanying drawings of accompanying drawings acquisition.
Fig. 1 is the hollow out gold target structural front view that the embodiment of the present invention one is provided；
Fig. 2 is the hollow out gold target structural front view that the embodiment of the present invention two is provided；
Fig. 3 is the partial enlarged drawing A of Fig. 2；
Fig. 4 is the hollow out gold target top view that the embodiment of the present invention one is provided；
Fig. 5 is the structural representation of the positioner that the embodiment of the present invention three is provided.
Reference：
1- gold sample bodies；The through holes of 2- second；3- first through hole；
4- medicament slow release casees；5- Nano medication layers；6- connects oxidant layer；
7- support arms；8-X ray emitters；9- receivers；
10- hollow outs gold mark.
Specific embodiment
Technical scheme is clearly and completely described below in conjunction with accompanying drawing, it is clear that described enforcement
Example is a part of embodiment of the invention, rather than the embodiment of whole.Based on the embodiment in the present invention, ordinary skill
The every other embodiment that personnel are obtained under the premise of creative work is not made, belongs to the scope of protection of the invention.
In describing the invention, it should be noted that term " " center ", " on ", D score, "left", "right", " vertical ",
The orientation or position relationship of the instruction such as " level ", " interior ", " outward " be based on orientation shown in the drawings or position relationship, merely to
Be easy to description the present invention and simplify description, rather than indicate or imply indication device or element must have specific orientation,
With specific azimuth configuration and operation, therefore it is not considered as limiting the invention.Additionally, term " first ", " second ",
" the 3rd " is only used for describing purpose, and it is not intended that indicating or implying relative importance.
In describing the invention, it should be noted that unless otherwise clearly defined and limited, term " installation ", " phase
Company ", " connection " should be interpreted broadly, for example, it may be being fixedly connected, or being detachably connected, or be integrally connected；Can
Being to be mechanically connected, or electrically connect；Can be joined directly together, it is also possible to be indirectly connected to by intermediary, Ke Yishi
The connection of two element internals.For the ordinary skill in the art, above-mentioned term can as the case may be understood
Concrete meaning in the present invention.
Embodiment one：
Fig. 1 is the structural front view of the hollow out gold mark 10 that the embodiment of the present invention one is provided, and Fig. 4 is carried for the embodiment of the present invention one
For hollow out gold mark 10 top view；As shown in Figure 1 and Figure 4, the hollow out gold mark 10 that the present invention is provided, including golden sample body 1, institute
State golden sample body 1 and offer first through hole 3 along its axis, the golden sample body 1 is in place in hollow shape, the first through hole 3
There are multiple medicament slow release casees 4, the golden sample body 1 radially opens up multiple second through holes 2, and the golden sample body 1 is hollow out
Structure.
The hollow out gold mark 10 that the present invention is provided, has the advantage that：
Golden sample body 1 is made for engraved structure, the golden sample body 1 of increase and implantation by the second through hole 2 on golden sample body 1
The stability of tumor tissues or the specific soft tissue around it, makes golden sample body 1 be not susceptible to movement, improves accuracy of detection, protects
The accuracy of card testing result；And the multiple medicament slow release casees 4 of placement are easy to the treatment to patient in first through hole 3, with knot
Structure is simple, it is easy to use the advantages of.
Further, the golden sample body 1 is hollow cylindrical.
Further, a diameter of 0.1mm-1.5mm of the golden sample body 1.
Further, second through hole 2 is circular shrinkage hole array, plum blossom-shaped hollow out array, circular hole overlapping array Huo Swastika
The shapes such as shape hollow out array.
Further, the length of the golden sample body 1 is 0.1mm-10mm.
Be respectively arranged with projection corresponding to the golden sample body 1 and medicament slow release case 4 in connection oxidant layer 6, golden sample body 1 or
The groove used with male cooperation is provided with medicament slow release case 4, raised structure is set and is caused the bonding of medicament slow release case 4 more
Firmly.
For the ease of using, the medicament slow release case 4 is fixedly connected on the golden sample body 1.The medicament slow release case 4
Inside it is placed with medicine.Projection can be provided with the golden inner surface of sample body 1, can arrange corresponding with projection on medicament slow release case 4
Groove, medicament slow release case 4 hung in the projection of golden sample body 1.Medicament slow release case 4 is built-in with high-purity antineoplastic, leads to
Cross the second through hole and be released slowly to focus the inside, directly play a part of to suppress or kill tumour cell.Go out for the ease of medicine
Come, through hole can be provided with medicament slow release case 4.Medicament slow release case 4 is cylindrical shape in the present embodiment, is built in hollow out
The inside of golden sample body 1.Further, in order to mitigate weight, medicament slow release case 4 could be arranged to hollow rectangular box.
Further, the connection oxidant layer 6 is biological adhesive phase.
The bioadhesive oxidant layer is fibrinogen layer, thrombin layer, casein layer, chitin layer or chitosan layer.
Collagen is boiomacromolecule, the main component in animal connective tissue, be also mammal in-vivo content most
The many, functional protein that distribution is most wide, accounts for the 25%～30% of total protein, and some organisms are even as high as more than 80%.
Collagen species is more, and common type is I type, II type, III type, V type and Ⅺ type.
Collagen because with good biocompatibility, biodegradable and biologically active, therefore in food, doctor
The fields such as medicine, organizational project, cosmetics are widely applied.The collagen health products " donkey-hide gelatin " of such as Chinese tradition, mainly
With donkey hide as raw material (being exactly in fact contained collagen in donkey hide), with higher nourishing health function, have Chinese medicine Triratna it
One good reputation.
Fibrin ferment：It is a kind of in human body anti-freezing, promotees the biologically active egg of important role in solidifying coagulation cascade reaction
In vain.
Casein layer：Casein is a kind of associated proteins of phosphorous calcium, and acid labile can be precipitated when pH is relatively low.
Casein be mammal include cow, the main protein in sheep and people's milk, also known as：Casein, casein, cheese
Element.
Chitin layer：Chitin (chitin) is also known as chitin.For the knot that N-acetyl-glucosamine is polymerized by β connections
Structure homopolysaccharide.In being widely present in the cell wall of the shell of shellfish, the crust of insect and fungi, some green algas are existed in
In；It is primarily used to as support body skeleton, and plays protection to body.
Chitosan layer：Shitosan (chitosan), also known as chitosan, is the chitin being widely present by nature
(chitin) obtain through deacetylation, chemical name is Chitosan (1-4) -2- amino-B-D glucose.
From 1859, Frenchman Rouget was obtained first after shitosan, the biological functionality of this natural polymer and phase
The premium properties such as capacitive, blood compatibility, security, microbic resolvability by all trades and professions extensive concern, medicine, food,
The application study of the numerous areas such as chemical industry, cosmetics, water process, METAL EXTRACTION and recovery, biochemical and biomedical engineering is obtained
Major progress.For patient, shitosan reducing blood lipid, the existing research report of hypoglycemic effect.Meanwhile, shitosan is by as increasing
Thick dose, fruit glaze agent list in state food additive use standard GB-2760.
Nano medication, to refer to and directly manipulate atom, molecule or atomic group, micel by certain microfabrication mode, makes
It rearranges combination, the new material with nanoscale of formation or structure, and one kind has with the kin phosphorus of biomembrane
The medicine of lipid bilayer structure carrier.
In drug research field, due to the continuous infiltration and impact of nanometer technology, cause the field depth of drug world one remote
Revolution, so as to occur in that Nano medication this new term.
Nano medication is referred to nanoscale high molecular nanometer grain (nano-particles, NP), nanosphere
(nano.spheres NS), nanocapsule (nano-capsules, NC) etc. are carrier, are combined together in a certain way with medicine
Medicine made by afterwards, its particle diameter can exceed that 100nm, but should be generally less than 500nm.Nano medication can also be directly by raw material
The nanoparticle that medicine is processed into.
The application of Nano medication not only improves the physicochemical property of pharmaceutical dosage form, and improves the targeting of medicine, delays
Property released etc..Research shows nano particle with high concentration medicine is directly acted on into cancer cell and avoids the energy of health tissues
Power.
The characteristic of Nano medication：
1) targeting under magnetic fields is combined using nano-carrier with magnetisable material so as to magnetic.
Meanwhile, by external complementary field, or by materials such as operation conduit, support of the implantation with magnetic field effect in body
Interior specific region forms magnetic field.Target organ is exposed in magnetic field, magnetic nano-carrier distribution in vivo is controlled with this so as to
Integrated distribution is in target organ.
There is research to show that magnetic nano-carrier can make its chemotherapeutics orientation for being loaded concentrate on targeting portion by magnetic field
Position (tumor tissues), improves the drug concentration of targeting moiety, strengthens therapeutic effect, while the drug concentration at other positions is reduced,
Reduce toxicity.
2) active targeting is by monoclonal antibody covalent cross-linking or is adsorbed onto nanoparticle surface, and formation is received with immunocompetence
The grain of rice, and be applied to the research of antineoplastic and also achieve certain result.
2nd, the controlled capability of Nano medication
Because of many chemotherapeutics half-life shorts, maintain its effective antitumor concentration-time shorter.Some chemotherapeutics are only right
Tumour cell in specific proliferating cycle plays a role, and the cell of other proliferating cycles is not played a role, but tumour
The cell cycle of cell is typically nonsynchronous, therefore, maintain long period effective blood concentration also non-for oncotherapy
It is often important.
3rd, Nano medication absorptivity is high
Nano medication is favorably improved the absorptivity of medicine, and drug-carrying nanometer particle can change film operative mechanism, increase medicine
To biomembranous permeability, be conducive to the performance of Drug Percutaneous Absorption and intracellular drug effect.
Such as loading the nanoparticle of antineoplastic adriamycin can make the more common adriamycin of its drug effect increase by 10 times, and reason is
The adhesiveness of drug-carrying nanometer particle and its little particle diameter can extend the medicine retention time, increase medicine and intestinal wall time of contact and
Contact area, improves the bioavailability of its oral absorption.
4th, nanometer antineoplastic is represented
The clinical antitumor agents for being currently based on nanometer technology are represented as liposomal doxorubicin, albumin combination type Japanese yew
Alcohol, micromolecular compound S63845, Chinese medical extract etc..
Wherein liposomal doxorubicin combines the bio distribution for changing medicine with lipidic nanoparticles for adriamycin, from
And the cardiac toxic of adriamycin is reduced, albumin combination type taxol also eliminates chemotherapeutics and organic solvent polyoxyethylene
The bad reaction of castor oil, it may not be necessary to directly applied using any solvent.
The medicine being currently in development also has BIND-014, and the medicine is targeting PSMA (PSMA)
Nanoparticulate drug containing docetaxel.
The display medicine is studied and good security, tolerance and effectively has late been achieved in patients with solid tumor
The result of property.
The nano particle of another kind of medicine filling gold element is proved that the Bb cells that can be killed in the people's cell of culture drench
Bar knurl, can suppress the lymphadenomatous growth of human B cell in mouse body in the case of non-chemotherapy.
And the targeting particle for being coated with Bladder cancer specific ligand and load taxol researched and developed is resistance to by 3 times of maximums
By dosage drug delivery to the mouse for having transplanted patient tumors, obtain good disease control and bad reaction be resistant to
Receive.
In terms of the treatment of Huppert's disease, nano particle also show certain potentiality, overcome using how soft
Than the resistance problems that star causes, through nano particle one of resistance acceptor Vla-4-4 (VLA-4) and micro-loop are avoided
Border interacts, and more directly, more effectively targeting is in tumour.
Further, the golden sample body 1 is made up of proof gold or is made up of titanium alloy, or other materials.
Proof gold refers to that 24K is golden, that is to say, that its gold content is 100%.But the gold of 24K is not there are in the world.Cause
This, on the market if the gold for indicating " 24K gold " or " proof gold " is neither real.
Proof gold content is referred to as " carat (measure of the purity of gold) " in gilding, and English is Karat, therefore referred to as karat gold.Commonly referred to as proof gold is 24K, that is, manage
It is 100% by upper gold content.
Golden target is suitable for protection domain：Stereotactic radiotherapy, linear accelerator, heavy particle therapy, proton therapeutic, spiral
The therapy fields such as tomography radiotherapy, self adaptation radiotherapy, termed image-guided radiotherapy.
Embodiment two：
Fig. 2 is the structural front view of the hollow out gold mark 10 that the embodiment of the present invention two is provided, and Fig. 3 is the partial enlarged drawing of Fig. 2
A；As shown in Figures 2 and 3, the described golden sample body 1 of the hollow out gold mark 10 that the present invention is provided is provided with Nano medication layer 5, in gold
Sample body 1 is provided with Nano medication layer 5 and is easy to the treatment to patient.
The Nano medication layer 5 is bonded on the golden sample body 1 by connection oxidant layer 6.Correspondence in the connection oxidant layer 6
The golden sample body 1 is provided with projection, on golden sample body 1 or Nano medication layer 5 groove used with male cooperation is provided with,
Arranging raised structure causes the bonding of Nano medication layer 5 more firm.The connection oxidant layer 6 is biological adhesive phase.
The bioadhesive oxidant layer is fibrinogen layer, thrombin layer, casein layer, chitin layer or chitosan layer.
It should be noted that golden sample body 1 is made up of proof gold or titanium alloy and is only intended to illustrate, golden sample body 1 is also
Can be made up of other materials, here just differs a citing.
Embodiment three：
Fig. 5 is the structural representation of the positioner that the embodiment of the present invention three is provided, as shown in figure 5, the present embodiment is provided
Hollow out gold mark 10 can by gold mark implanted device implantation, implanted device include injection needle body and above-mentioned hollow out gold mark 10, institute
State golden sample body 1 to be placed in the injection needle body.
Present invention also offers a kind of gold mark positioner, including described hollow out gold mark 10, wherein, also include corresponding to
The X-ray emitter 8 that the golden sample body 1 is arranged.
When using, the top of support arm 7 of c-type is provided with X-ray emitter 8, and bottom is provided with receiver 9, launches X-ray,
The radioscopic image of hollow out gold mark 10 is obtained on receiver 9, image information is preserved, so as to realize the positioning to target device pipe.
Finally it should be noted that：Various embodiments above only to illustrate technical scheme, rather than a limitation；To the greatest extent
Pipe has been described in detail with reference to foregoing embodiments to the present invention, it will be understood by those within the art that：Its according to
So the technical scheme described in foregoing embodiments can be modified, either which part or all technical characteristic are entered
Row equivalent；And these modifications or replacement, do not make the essence disengaging various embodiments of the present invention technology of appropriate technical solution
The scope of scheme.
Claims (10)
1. a kind of hollow out gold is marked, it is characterised in that including golden sample body, and the golden sample body offers first and leads to along its axis
Hole, the golden sample body is in hollow shape, and multiple medicament slow release casees are placed with the first through hole, and the golden sample body is along its footpath
To multiple second through holes are opened up, the golden sample body is engraved structure.
2. hollow out gold according to claim 1 is marked, it is characterised in that the golden sample body is hollow cylindrical.
3. hollow out gold according to claim 2 is marked, it is characterised in that a diameter of 0.1mm-1.5mm of the golden sample body.
4. hollow out gold according to claim 1 is marked, it is characterised in that second through hole is circular shrinkage hole array, plum blossom
Shape hollow out array Huo Swastika shape hollow out arrays.
5. hollow out gold according to claim 1 is marked, it is characterised in that the length of the golden sample body is 0.1mm-10mm.
6. hollow out gold according to claim 1 is marked, it is characterised in that the medicament slow release case is bonded to by connecting oxidant layer
On the golden sample body.
7. hollow out according to claim 6 gold mark, it is characterised in that the connection oxidant layer is made a living thing adhesive phase.
8. hollow out gold according to claim 1 is marked, it is characterised in that the golden sample body is made up of proof gold.
9. hollow out gold according to claim 1 is marked, it is characterised in that the golden sample body is made up of titanium alloy.
10. a kind of gold mark positioner, marks including the hollow out gold according to any one of claim 1-9, it is characterised in that
Also include the X-ray emitter arranged corresponding to the golden sample body.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710067198.9A CN106621077A (en) | 2017-02-06 | 2017-02-06 | Hollowed-out gold mark and gold mark location device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710067198.9A CN106621077A (en) | 2017-02-06 | 2017-02-06 | Hollowed-out gold mark and gold mark location device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106621077A true CN106621077A (en) | 2017-05-10 |
Family
ID=58845211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710067198.9A Pending CN106621077A (en) | 2017-02-06 | 2017-02-06 | Hollowed-out gold mark and gold mark location device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106621077A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174330B1 (en) * | 1997-08-01 | 2001-01-16 | Schneider (Usa) Inc | Bioabsorbable marker having radiopaque constituents |
| US20040109823A1 (en) * | 2000-11-16 | 2004-06-10 | Microspherix Llc | Flexible and/or elastic brachytherapy seed or strand |
| US20070238983A1 (en) * | 2006-01-20 | 2007-10-11 | Krishnan Suthanthiran | Fiduciary Markers and Method of Use thereof |
| US20090240140A1 (en) * | 2008-01-29 | 2009-09-24 | Superdimension, Ltd. | Target Identification Tool For Intra-Body Localization |
| CN103691066A (en) * | 2013-12-27 | 2014-04-02 | 成都军区昆明总医院 | Gold labeling implant and manufacture method thereof |
| CN105251126A (en) * | 2015-11-17 | 2016-01-20 | 中国人民解放军第二军医大学 | Tracking marker for stereotactic radiation therapy (SRT) |
| CN106334273A (en) * | 2015-07-08 | 2017-01-18 | 中国人民解放军总医院 | Radiotherapy tracking and locating marker and implantable puncture needle provided with same |
-
2017
- 2017-02-06 CN CN201710067198.9A patent/CN106621077A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174330B1 (en) * | 1997-08-01 | 2001-01-16 | Schneider (Usa) Inc | Bioabsorbable marker having radiopaque constituents |
| US20040109823A1 (en) * | 2000-11-16 | 2004-06-10 | Microspherix Llc | Flexible and/or elastic brachytherapy seed or strand |
| US20070238983A1 (en) * | 2006-01-20 | 2007-10-11 | Krishnan Suthanthiran | Fiduciary Markers and Method of Use thereof |
| US20090240140A1 (en) * | 2008-01-29 | 2009-09-24 | Superdimension, Ltd. | Target Identification Tool For Intra-Body Localization |
| CN103691066A (en) * | 2013-12-27 | 2014-04-02 | 成都军区昆明总医院 | Gold labeling implant and manufacture method thereof |
| CN106334273A (en) * | 2015-07-08 | 2017-01-18 | 中国人民解放军总医院 | Radiotherapy tracking and locating marker and implantable puncture needle provided with same |
| CN105251126A (en) * | 2015-11-17 | 2016-01-20 | 中国人民解放军第二军医大学 | Tracking marker for stereotactic radiation therapy (SRT) |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105288622B (en) | The preparation method of chemotherapeutics and the cell membrane vesicles of optical dynamic therapy medicine is loaded simultaneously | |
| Yang et al. | NIR-activated self-sensitized polymeric micelles for enhanced cancer chemo-photothermal therapy | |
| CN106691598A (en) | Gold mark with coating and coating location device | |
| CN106699896A (en) | Tumor killing polypeptide capable of being self-assembled into hydrogel and application thereof | |
| CN105669964A (en) | Ovarian cancer specifically targeted biodegradable amphiphilic polymer, polymer vesicle prepared from same and application of amphiphilic polymer | |
| CN104490786B (en) | Preparation method and application of targeted multi-function double drug-loading liposome | |
| CN109875964A (en) | A kind of preparation and its application of adriamycin carrier-free Nano medication | |
| Rajasekharreddy et al. | Green synthesized nanomaterials as theranostic platforms for cancer treatment: Principles, challenges and the road ahead | |
| CN104721131B (en) | A kind of gel preparation and preparation method for neoplasm in situ treatment | |
| Yin et al. | Precisely translating computed tomography diagnosis accuracy into therapeutic intervention by a carbon-iodine conjugated polymer | |
| CN207084858U (en) | Band coating gold mark and gold mark positioner | |
| CN104940951B (en) | A kind of preparation method of magnetizing reduction response antineoplastic drug carrier | |
| CN105663043A (en) | 131I-labelled c(RGDyk)-targeting doxorubicin thermosensitive nanoliposome and preparation and application thereof | |
| CN207076028U (en) | Hollow out gold mark and gold mark positioner | |
| CN106621077A (en) | Hollowed-out gold mark and gold mark location device | |
| CN106606783B (en) | A kind of targeting is passed altogether to be released the drug of photosensitizer and chemotherapeutics and passs release system | |
| CN207076027U (en) | Titanium alloy gold mark implant and gold mark emitter | |
| Liu et al. | Injectable fiducial marker for image-guided radiation therapy based on gold nanoparticles and a body temperature-activated gel-forming system | |
| CN106344513A (en) | Mitochondrion-targeted micelle material and curcumin micelle preparation prepared from material | |
| CN207075934U (en) | Proof gold gold mark implant and gold mark emitter | |
| CN110251672A (en) | A kind of nanometer of diagnosis and treatment agent and the preparation method and application thereof | |
| EP3280452B1 (en) | Fiducial marker for use in stereotactic radiosurgery and process of production | |
| CN106693216A (en) | Titanium alloy gold label implant and gold label syringe | |
| CN207520449U (en) | Negative thread gold mark implant and gold mark emitter | |
| CN207520462U (en) | Male thread gold mark implant and gold mark emitter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230525 Address after: No. 35-8 Huishen Road, Xuefu Industrial Zone, Xiqing District, Tianjin, 300000 Applicant after: Zhongke Yingde (Tianjin) Health Industry Development Co.,Ltd. Address before: No. 241, Office Building, Former Hade Company Factory, Guanqitou Industrial Community, Donggang Street, Putuo District, Zhoushan City, Zhejiang Province, 316000 Applicant before: ZHEJIANG RONGCHENG MEDICAL TECHNOLOGY Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20240419 |
|
| AD01 | Patent right deemed abandoned |